A biotech giant based in Ventura County agreed to pay more than $760 million dollars to settle charge that it marketed one of its drugs for unapproved uses.
The U.S. Attorney’s Office in New York says Amgen pled guilty to illegally introducing a misbranded drug into interstate commerce, and will pay a total of $150 million dollars.
The issue was the marketing of the anemia drug Aranesp.
A law firm says the Thousand Oaks company will also pay more than $600 million dollars to settle civil litigation involved with the case.
However, that deal hasn’t been confirmed by prosecutors. A judge will decide today whether to accept the plea, and settlement in the case.